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Background: Sepsis complication is a major cause of death in multiple trauma critically ill patients. Defensin
(cysteine rich anti-microbial peptides), as an important component of immune system, might play an important
role in this process. There is also rising data on immunological effects of N-acetyl-cysteine (NAC), a commonly used
anti-oxidant in oxidative stress conditions and glutathione (GSH) deficiencies. The aim of the present study was to
evaluate the potential beneficial effects of NAC administration on multiple trauma patients with sepsis.
Methods: In a prospective, randomized controlled study, 44 multiple trauma critically ill patients who were
mechanically ventilated and met the criteria of sepsis and admitted to the intensive care unit (ICU) were
randomized into two groups . Control group received all standard ICU therapies and NAC group received
intravenous NAC 3 gr every 6 hours for 72 hours in addition to standard therapies. Acute Physiology and Chronic
Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, length of ICU stay, ICU
mortality were recorded. Levels of serum Immunoglobulin M (IgM), Human β-Defensin 2 (HβD2) and GSH were
assessed at baseline and 24, 72, 120 hours after intervention.
Results: During a period of 13-month screening, 44 patients underwent randomization but 5 patients had to be
excluded. 21 patients in NAC group and 18 patients in control group completed the study. For both groups the
length of ICU stay, SOFA score and systemic oxygenation were similar. Mortality rate (40% vs. 22% respectively,
p = 0.209) and ventilator days (Mean ± SD 19.82 ± 19.55 days vs. 13.82 ± 11.89 days respectively, p = 0.266) were
slightly higher for NAC group. IgM and GSH levels were similar between two groups (p = 0.325, 0.125 respectively),
HβD2 levels were higher for NAC group (at day 3).
Conclusion: High dose of NAC administration not only did not improve patients’ outcome, but also raised the risk
of inflammation and was associated with increased serum creatinine.
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Multiple trauma, SepsisBackground
Multiple trauma, a complex syndrome of injuries to vari-
ous anatomical regions with defined intensity and subse-
quent systemic reactions [1]. Trauma is the major cause
of death before the age of 45 in developed countries
[2,3], claiming over 6 million kills annually around the* Correspondence: aarezoo24@gmail.com
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unless otherwise stated.world which is preventable in approximately 20% of
cases [4,5]. Three pre-eminent causes of death in this
patients are head trauma, hemorrhage and sepsis/Multi
Organ Failure (MOF) [6]. Tissue ischemia induces Reactive
Oxygen Species (ROS) production which in turn activates
neutrophils and attracts them to the injury site. Extensive
progression of this and other similar processes following
trauma insult enhance the local inflammatory response to
remote organs, resulting in the development of Systemic
Inflammatory Response Syndrome (SIRS) [7-12]. In sepsis,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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pro-inflammatory cytokines [Interleukin 1(IL-1), Tumor
Necrosis Factor α (TNF-α)] trigger target cells (leukocytes,
endothelial cells, hepatocytes, lung and intestine epithelium)
and induce cytokine, chemokine, ROS and proteolytic
enzymes production [13-16].
It is obvious that patients with sepsis or multiple trauma
require mechanical ventilation support. Due to the high
concentration of inspired oxygen used, the probability of
alveolar epithelial damage is high as the result of forma-
tion of free oxygen radicals. Some studies have suggested
that the use of high doses of antioxidants in these patients
could be beneficial [7].
Defensins are cysteine rich endogenous antimicrobial
peptides which consist of to approximately 5% of total
granulocyte proteins, following infection their levels in
systemic circulation increases, defensins have a significant
effect on a wide spectrum of microorganisms [17-19] and
beyond that they also act as immunologic mediators [20].
Human β Defensin 2 (HβD2) is an inducible defensin,
whose induction is impaired during sepsis [20,21].
NAC is a well-known anti-oxidant which is administered
in various conditions where oxidative stress is present
[22-24]. NAC is thiol containing compound that in addition
to direct radical scavenging properties is a precursor for
glutathione (GSH) synthesis [23,24]. NAC seems to have
immunological effects (doses higher than 12 gram/day) that
can affect different cytokines (IL-2, IL-4, IL-6, IL-10, TNF-α,
NF-κB) [25,26] and phagocytic function [27]. NAC has re-
ceived so much credit for its nephro-protective properties
when used prior to radio-contrast media administration.
The ischemia compounded by increased medullary O2con-
sumption may somewhat resemble ischemic acute tubular
necrosis (ATN) in trauma and sepsis. Although near 10
Meta-Analyses has been published to justify its use many of
these studies have significant pitfalls [25-27].
To our knowledge there are no studies about the effect
of NAC as an antioxidant and/or immunomodulator in pa-
tients with SIRS/sepsis criteria following multiple trauma.
Therefore, this study aimed to investigate HβD2 levels in
multiple trauma patients with SIRS/sepsis and its potential
correlation with progress and outcome of therapy, and to
evaluate the effects of high dose NAC administration, in
the early onset of sepsis during first hours to days after
trauma, on immunologic responses and overall outcome.
Furthermore, this study sought to examine the hypothesis
that NAC administration can alter HβD2 levels either by
immuno-modulatory activity or as a cysteine source.
Methods
Study design and patient population
Between March 2011 to April 2012, this prospective ran-
domized clinical trial was conducted in general ICU of
“Sina”and “Imam Khomeini” Hospital of Tehran Universityof Medical Sciences (TUMS), Iran. In all cases, in-
formed consents were received from their legal guard-
ian. The study protocol was approved by the ethical
committee of TUMS. Our clinical trial was registered in
Iranian Registry of Clinical Trial with code number of
(IRCT 2014010716120 N1).
All the patients enrolled in the study had multiple
trauma. The inclusion criteria were age older than 18 years,
mechanical ventilation with FiO2 more than 50%, an Acute
Physiology and Chronic Health Evaluation (APACHE) II
score greater than 15, suspected infection and at least two
Systemic Inflammatory Response (SIRS) criteria (defined
as the following conditions: body temperature > 38°C
or < 36°C, heart rate > 90 beats/min, respiratory rate > 20
breath/min or Paco2 < 32 mmHg, WBC >12,000 cells/mm
3,
or < 4000 cells/mm3, or > 10% immature [band] cells)
diagnosed during the first 24 hours of ICU admission.
Exclusion criteria for all patients were ages below
18 years, pregnancy, breast feeding, beyond 24 hours of sep-
sis diagnosis, Central Venous Pressure (CVP) > 18 mmHg,
Systolic Blood Pressure < 90 mmHg or Mean Arterial
Pressure (MAP) < 60 mmHg, Serum Creatinine ≥ 2 mg/dl,
liver dysfunction (defined as the presence of hepatic
cirrhosis or concentration of serum transaminases
greater than third times the upper limit of normal range),
history of myocardial infarction or heart failure (EF < 40%)
and those received N-acetyl Cysteine (NAC) before initi-
ation of study.
Patients were randomized via block randomization to
receive one of the following treatments: standard treat-
ment for sepsis (control group) and standard treatment
plus NAC (intervention group) for 72 hours. Standard
treatments for sepsis were implemented as following:
early resuscitation within the first 6 hours of admission,
appropriate diagnostic studies to ascertain causative or-
ganisms before starting antibiotics, early administration
of broad-spectrum antibiotic therapy, reassessment of
antibiotic therapy with microbiology and clinical data to
narrow coverage, appropriate Volume resuscitation or
vasopressor therapy, Mechanical ventilation adjusted to
maintain SaO2 > 95%, PaO2 > 90 mmHg and PaCO2 be-
tween 38 and 42 mmHg, appropriate analgesia and sed-
ation provided for all patients, insulin treatment was
administered to maintain glucose at < 200 mg/dl and ap-
propriate prophylactic measures for deep vein thrombosis
(DVT) and stress-related mucosal damage (SRMD). Pa-
tients in intervention group received intravenous NAC
(Exir Pharmaceutical company, Tehran, Iran) 3gr in 250 ml
5% dextrose over 30 min every 6 hours for the first
72 hours of admission (Figure 1).
Demographic data and clinical information were ob-
tained at the beginning. Monitoring parameters includ-
ing MAP, heart rate, respiratory rate and CVP of each
patient were recorded in the ICU flow sheets every
Figure 1 Enrollment and protocol study.
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Blood Urea Nitrogen (BUN), hemoglobin, platelet and
white blood cell (WBC) counts, albumin, sodium and po-
tassium were also collected daily during 5 days of study
period.
Measurements
All patients had central venous catheter and arterial cath-
eter for blood sampling. For all patients there were four
scheduled time points to assess the level of IgM, GSH and
HβD2. Blood samples were collected at baseline and 24,
72 and 120 hours after intervention and centrifuged at
3000 × g for 15 minutes to remove cells and cellular deb-
ris. The plasma stored at −80°C until the time of analysis.
Levels of IgM, GSH and HβD2 were measured by com-
mercially available enzyme-linked immunosorbent assay
(ELISA) kits (CUSABIO® biotech co LTD, Wuhan Hubei,
China) according to manufacturer instruction.
APACHE score was measured at the beginning and
Sequential organ failure assessment (SOFA) score was cal-
culated daily for 5 days. Length of ICU stay, ICU mortality
and ventilator free days were recorded for all patients.
Statistical Analysis
All data were expressed as Mean ± SD. The unpaired t test
for parametric data and Mann–Whitney test for nonpara-
metric data were used to compare the differences between
the treatment groups at each time point. Comparisons of
the differences between the time points in each treatment
group, repeated-measure one-way analysis of variance
and nonparametric analysis of variance (Friedman test)were performed to analyze changes in levels of the
biomarkers. The paired t test for parametric data and
Wilcoxon rank sum test for nonparametric data were
done to analyze changes in variables with 2 time points
(at baseline and 24 hours after). P values less than 0.05
were considered statistically significant.
Results
Between March 2011 to April 2012, 44 consecutive pa-
tients who met the inclusion criteria were enrolled in
the study. Five patients excluded from the study, three
of them died before the end of the study and the other 2
patients received NAC dosage other than the study
protocol. The remaining 39 patients were randomly
assigned to NAC group and control group, each with 21
and 18 patients respectively. Demographic and baseline
values for APACHE and SOFA scores have been sum-
marized in Table 1. The differences in age and sex were
not significant between two groups. (p = 0.450 and 0.204
respectively). Differences in baseline values for APACHE
and SOFA scores were not statistically significant either
(Table 1). Also the patients in each group were similar at
baseline regarding to heart rate, MAP, temperature and
Pao2/Fio2 (Table 1).
In comparison between two groups, in NAC group,
ventilator days were longer (19.82 ± 19.55 vs. 13.82 ±
11.69 days), length of ICU stay was shorter (21.2 ± 20.71
vs. 27.72 ± 39.46 days) and mortality rate was higher
(40% versus 22%), although the differences in ventilator
days, length of ICU stay and mortality rate were not
statistically significant (p = 0.266, p = 0.545, p = 0.209
Table 1 Demographic and baseline clinical characteristic
of patients
Control group NAC group P value
Age (years) 44.44 ± 17.684 40.14 ± 17.828 0.450
Male number 15 20 0.204
APACHE II 20.06 ± 5.162 21.05 ± 512 0.476
SOFA 7.28 ± 2.109 6.86 ± 1.457 0.468
GCS 7.28 ± 1.934 6.55 ± 1.143 0.145
MAP(mmHg) 92.72 ± 17.376 93.39 ± 14.467 0.899
HR(beat/min) 89.94 ± 18.005 97.09 ± 19.079 0.234
Temperature(°C) 37.339 ± 1.01 37.145 ± 0.965 0.536
PaO2/FiO2 196.607 ± 105.504 219.594 ± 123.307 0.529
SCr(mg/dl) 1.046± 1.053 ± 0.373 0.945
NAC: N-Acetylcysteine, APACHE: Acute Physiology and Chronic Health
Evaluation, SOFA: Sequential Organ Failure Assessment, GCS: Glasgow Coma
Scale, MAP: Mean Arterial Pressure, HR: Heart Rate.
Data shown as Mean ± SD. P values <0.05 consired significant.
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with a trend towards a reduction in NAC group spe-
cially on day 3 but the trend was not statistically signifi-
cant (Figure 2).
Pao2:Fio2 ratio improved in both groups (specially in
the NAC group on day 3), although the difference was
not significant (p = 0.567) (Figure 3). An upward trend
in MAP, heart rate, WBC counts and Absolute Neutrophil
Count (ANC) were shown in NAC group on day 1 through
5 after the start of NAC (Table 2). By means of paired t-test
(before-after analysis) method, we had a significant decline
in mean serum creatinine level between 1–3 days in control
group (1.04 ± 0.25 versus 0.891 ± 0.253 p = 0.019). The
mean serum creatinine level rose on day 1 through 3 in
NAC group, however; this increase was not statistically
significant (1.05 ± 0.373 versus 1.48 ± 2.87, p = 0.514). On
day 5, creatinine levels reached similar levels in both
groups (0.851 ± 0.205 Control group versus 0.920 ± 0.385
NAC group p = 0.502).Figure 2 Changes of patients SOFA score in different days of study. Dif
mean SOFA score±SE.Furthermore the changes in the level of IgM (p = 0.325)
and GSH (p = 0.125) were not significant among two
groups but the mean serum levels of GSH were higher in
NAC group (Table 3). Despite a non significant difference
in HβD2 levels between two groups (p = 0.463), HβD2
levels are associated with a trend towards an increase in
NAC group specially on day 3 (Figure 4).
Discussion
The aim of the current study was to focus on potential
immunological effects of NAC administration in critical
illness, we have also reassessed the antioxidant proper-
ties which had already been well established. In previous
study, immunological effects of NAC were seen with
doses relatively higher than usual dosage for anti-
oxidant effects (higher than 9 gram/day) [25-27]. So we
have administered 12 gram/day of NAC in our study.
The previous study [24] reviewed the effects of NAC in
a condition of GSH deficiency such as pulmonary
disease and oxidative stress, they concluded that oral ad-
ministration of NAC was a safe and beneficial supple-
ment in setting of GSH deficiency. In other study
conducted on piglets, it was observed that NAC has no
significant effect on the total GSH level [28]. Another
study investigated the effects of NAC (150 mg/kg bolus
and then 12 mg/kg/day as continuous infusion for 3–5
days) on total antioxidant potential in 60 critically ill pa-
tients [29]. The need for inotropic support and mechan-
ical ventilation and ICU stay did not vary significantly
between NAC and placebo group. Also levels of total
antioxidant potential remain unchanged during inter-
vention. Other study evaluates the effects of NAC
(150 mg/kg bolus followed by a continuous infusion of
12 mg/kg/hr from a minimum of 3 days up to a max-
imum of 5 days) for prevention of multisystem organ
failure [30]. The mortality, the required days of ino-
tropic support, mechanical ventilation, and intensive
care did not significantly change between two groups.ference between two groups is not significant (P=0.708). Figure shows
Figure 3 Changes of Pao2/Fio2 ratio in patients in different days of study. Difference between two groups is not significant (P = 0.567).
Figure shows mean ±SE.
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admission had a significantly worse mortality in the
NAC group as well. Indeed, during 10 years ago several
clinical randomized trials suggested that the beneficial
impact of NAC were achieved if given early, due to attenu-
ating inflammatory response by free radical scavenging ef-
fects, but if commenced in a later phase of sepsis, it may
also worsen outcome, as a result of the impaired granulo-
cyte – dependent bacterial killing [30-32]. Nevertheless,
prophylactic NAC treatment failed to prevent postoper-
ative organ dysfunction following major abdominal sur-
gery [33].
The results of this study show that high doses of NAC
(12 gram/day) for the first 72 hours in mechanically ven-
tilated multiple trauma patients with sepsis patients (pa-
tients with sepsis diagnosis over 24 hour was excluded),
do not significantly change in the total serum GSH level.
Meanwhile in NAC group, the mean level of GSH is
higher than control group, it is not along with any im-
provement in outcome. The ventilator day and mortality
rate are higher in NAC group and it shows a negative
impact on HR and MAP as well. Our data suggests re-
consideration and conducts large sized trials in order to
evaluate the efficacy of NAC as an anti-oxidant and a thiol
group supplement for GSH deficiency. Further studies areTable 2 Changes of patients HR, MAP, WBC count, ANC in dif
Base line Day 1 D
HR Control 89.94 90.67 8
Intervention 96.43 97.19 9
MAP Control 91.18 80.29 8
Intervention 94.48 89.29 9
WBC count Control 11726 10597 8
Intervention 13094 11791 1
ANC Control 10306.07 7737.73 7
Intervention 10261.22 9507.84 8
MAP: Mean Arterial Pressure, HR: Heart Rate, ANC: Absolute Neutrophil Count.recommended to conduct with focus on commencing
NAC treatment in an earlier phase of sepsis, dosage and
safety issues. In our study we have observed that NAC,
which is often considered as a safe and well tolerated
entity, is not as safe. Furthermore, in some circum-
stances its indication is questionable and present data
are not satisfactory.
We have assessed systemic oxygenation and respira-
tory functions in terms of changes in PaO2/FiO2 ratio
and the number of ventilator days. In other study ad-
ministered 190 mg/kg/day NAC as continuous infusion
for 3 days in 42 patients with established Acute Respira-
tory Distress Syndrome (ARDS) and compared it with
placebo [34]. The mortality rate, the need for ventilator
support and ICU stay and PaO2/FiO2 ratio did not differ
significantly between both groups. In another random-
ized double-blind, placebo controlled clinical trial by
Bernard et al. NAC 70 mg/kg every 8 hours was admin-
istered for ARDS patients for 10 days [35]. The number
of days of acute lung injury decreased in NAC group, yet
mortality rate did not change significantly between
groups. In our study we encounter similar results. The
analyses show no significant difference on day 1 through
5. Improvement in Pao2/Fio2 ratio is seen on day 5 in
both groups. The number of ventilator days is longer forferent days of study
ay 2 Day 3 Day 4 Day 5 P. value
7.89 84.67 86.56 89.00 0.040
7.81 100.86 97.67 94.19
7.47 85.12 83.71 82.53 0.042
2.05 94.33 90.95 89.95
930 7890 8117 89 0.06
0165 10874 11087 11191
425.16 5804.00 5569.42 6732.95 0.001
468.47 9800.79 9754.49
Table 3 Changes of patients IgM and GSH level in different days of study
Base line Day1 Day3 Day5
IgM(mg/dl) Control 35.28 ± 8.67 34.59 ± 8.87 32.00 ± 2.69 34.43 ± 5.69
NAC 34.22 ± 6.38 33.35 ± 6.80 32.18 ± 6.28 31.64 ± 3.93
GSH(μg/dl) Control 11.89 ± 8.95 11.05 ± 9.52 10.99 ± 7.20 9.26 ± 6.76
NAC 15.9 ± 9.55 14.79 ± 12.89 15.35 ± 9.51 13.51 ± 6.76
NAC: N-AcetylCysteine, IgM: Immunoglobulin M, GSH: Gluthathione, Data are shown as Mean ± SD.
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significant. We can suggest that routine administration
high dose of NAC has no effect on ventilator days and
can be harmful.
Various studies have investigated the potential effect of
NAC on immune system function in different setting
(animal and human studies) and focused on diverse
pathological conditions (ARDS, SIRS or sepsis, hepatic
injury and etc.). For instance, in other study in critically
ill patients with SIRS or sepsis noticed that, high doses
of NAC (12, 18 gram/day) resulted in significantly im-
proved phagocytic activity of neutrophils as compared
with low doses of NAC. In contrast, they found that high
dose NAC decreases respiratory burst and leads to im-
paired clearance of microorganisms [27].
Santiago and co-workers investigated NAC’s effects on
inflammatory response and reported that plasma IL-4
and IL-10 (anti-inflammatory cytokines) levels were
higher in NAC treated group with respect to time of hep-
atic reperfusion, indicating a positive modulation effect of
NAC on the anti inflammatory response mediated by this
cytokines [25]. In in-vitro settings, NAC with similar con-
centrations above 25 mmol/L completely inhibited NF-κB
signal. The trend was the same in in-vivo part of the study,
Paterson and colleagues reported. A significant decrease
in IL-8 levels in severe sepsis patients treated with NAC,
while NAC had no effect on IL-6 levels as reported in
that study [26]. Several studies evaluated the immune-Figure 4 Changes in Serum HβD2 in different days of study. Difference bmodulating effects of NAC and its usage in sepsis, but
the results were contradictory. Considerable amount of
evidence showed that NAC administration suppressed
neutrophils and macrophages activation, attenuating
leukocyte–endothelial cell adhesion and inhibited TNF-α
and IL-8 release [26,36-38]. Emet and co-workers reported
that early NAC administration in severe sepsis did not
affect cytokine levels [38,39].
In the current study, immune-modulating effect is eval-
uated by white blood cell count, absolute neutrophil count
and serum IgM levels. In NAC group, WBC count and
subsequently ANC are higher than control group which
would be indicated more extensive inflammatory condi-
tion. The consistent tachycardia, elevated serum creatin-
ine levels and higher 28 days mortality rate have observed
in NAC group allegedly support these findings. IgM levels
decrease from1 day through 5 in both groups. All patients
are IgM deficient and NAC administration neither in-
crease nor decrease IgM levels and it seems that no im-
mune modulation properties are found in high doses of
NAC.
Cysteine rich endogenous anti-microbial peptide HβD2
is an important component of immune system (Innate
and adaptive) [20,40-43]. This study attempt to investigate
whether HβD2 level can be accounted as a marker of SIRS
or sepsis. In addition, the study also investigate whether
NAC administration (as a cysteine source with probable
immune-modulating properties) can elevate HβD2 levelsetween two groups is not significant (P = 0.463). Figure shows mean±SE.
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defensins). Attributed roles to HβD2 in immune system
are controversial, yet it is not clear whether HβD2 is an
anti-inflammatory protective mediator during sepsis or
vice versa. In other study, no difference was observed be-
tween survivors and non-survivors of severe sepsis and
critical illness in terms of HβD2 levels. Ex-vivo inducible
expression of HβD2 by peripheral blood cells was im-
paired in samples from patients with severe sepsis but this
was not along with low levels of HβD2, interestingly
HβD2 levels were significantly higher in patients with se-
vere sepsis compared to non-septic critically ill and
healthy controls. Which according to Chen et al., NF-κB
was as crucial factor for activation of HβD2 gene. In con-
clusion Book and coworkers noted that up-regulation of
HβD2 in sepsis occurred as a result of elevated pro-
inflammatory cytokines (such as IL-1 and TNF) [46,47]
and was an indicator of higher activity of inflammation
and the availability of sources other than peripheral blood
cells for HβD2 [21].
Circulating defensins were increased in non-neutropenic
children with systemic infection and sepsis. Neutrophils
were the major source of defensins, they served as a spe-
cific marker for PMN activation. Defensins were not asso-
ciated with organ failure or poor outcome during sepsis,
defensins released into systemic circulation is an indicator
of host response to sepsis. These were observations from
Thomas and colleagues in a study on levels of HβD2 and
lactoferrin in children with severe sepsis, the reported
range by them was 450 ng/ml (median) and 194–1032
(25%-75% range) for day 1, and 300 nano-gram/ml (me-
dian) and 75–681 (25%-75% range) [41].
We hypothesized that NAC as a cysteine rich source
could increase HβD2 levels and our result has con-
firmed this hypothesis. According to the results of our
study, HβD2 levels are associated with an upward trend
in NAC and a downward trend in control group. The
difference between means of the two groups, however
were only noteworthy on day 3. Results indicate that
NAC administration with such dosage may have in-
duced HβD2 expression. Regarding the previous discus-
sion on immune-modulating effect of NAC, the elevated
HβD2 levels in response to NAC administration appears
to be the consequence of profound cysteine source. In
our survey, despite higher level of HβD2 in SIRS and
sepsis, no potential benefits were found concerning
SOFA score and outcome (evaluated based on 28 days
mortality rate and ICU length of stay). In accordance
with our results supposedly considered as a marker of
inflammation in patients with sepsis, however, due to
limitations of our study regarding sample size, difficul-
ties in measuring other defensin subtypes with corre-
sponding structure and lack of data on important
cytokines like IL-1 and TNF, further studies arenecessary in order to clarify HβD2 and other defensin
activities and characterization of potential therapeutic
or diagnostic targets.
One of the possible protective effects of NAC as a pre-
ventive in contrast induced nephropathy still remains un-
determined. Based on various studies and meta -analyses
NAC administration decreases the risk of contrast in-
duced nephropathy [48-52]. In addition NAC may at-
tenuate contrast induced nephropathy, as defined by
albumin excretion, and seems to be independent of any
effect on creatinine (NAC dosage: 500 mg IV prior to
cardiac catheterization) [53].
Marenzi et al. suggested that NAC should have a pro-
tective effect solely when oxidative stress, induced by
ischemia and reperfusion, is present (NAC dosage:
600 mg intravenous bolus before primary angioplasty
and 600 mg orally twice daily for the 48 hours after
angioplasty) [54]. Carbonell et al. found NAC’s protect
in the prevention of contrast induced nephropathy is
based on reducing serum creatinine (SrCr) levels. The
incidence of contrast induced nephropathy was signifi-
cantly lower in NAC group but this effect was only valu-
able in high risk patients considering similar results that
normal saline hydration produced in patients with nor-
mal renal function [55,56]. In conclusion Carbonell and
coworkers recommend intravenous NAC prior to coron-
ary angioplasty in high risk patients with SrCr ≥1.4 mg/dl,
especially when hydration is impossible (NAC dosage:
600 mg every 12 hours IV) [56]. Macedo et al. in a study
with focus on acute renal failure (ARF) associated with
elective aortic aneurysm repair surgery, did not observe
a change in ARF incidence and SrCr peak by NAC
administration, in summary the study implied that po-
tential beneficial effects of NAC in prevention of radio-
contrast induced nephropathy should not be generalized
to other insults applied to kidneys (NAC dosage: 1200 mg
orally twice daily 24 hours before and 600 mg IV twice
daily for 48 hours after) [57].
In chronic kidney disease (CKD) patients, some ben-
efits has been observed by NAC, NAC reduces cardio-
vascular events in patients with stage 5 CKD and
improves nitric oxide bioavailability (NAC dosage:
Tepel et al., 600 mg Twice daily orally, Efrati et al. 1gr
IV twice daily, 24 hours before and after angiography)
[58,59]. Wittstock et al. demonstrated administration
of NAC during dialysis session significantly improved
arterial vascular reactivity in end stage CKD patients
(NAC dosage: 5 gram IV during dialysis session) [60].
Contrary to that Renke et al. had reported, NAC had
no effect on proteinuria and markers of tubular and renal
fibrosis in non-diabetic CKD patients (NAC dosage:
1200 mg/day orally) [61].
In a study by Rosato and coworkers who evaluated the
NAC effects on vascular system function in Systemic
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vascular renal function in patients with low severity of dis-
ease (NAC dosage: 15 mg/kg/hour for 5 hours) [62].
Our study was not designed to assess how NAC affects
the kidneys function, not to mention the fact that the dos-
age of NAC administered in this study was higher than
dosages administered in studies on nephro-protective
properties. Considering that rising in SrCr levels is notice-
able. Using paired t-test (before after analysis) statistical
method shows a significant increase in the mean of SrCr
level in NAC group while at the same time the mean level
of SrCr in control group is reduced. The mean level of
SrCr during NAC administration have reached 1.48 mg/dl
on day 3 and interestingly SrCr levels after discontinuation
of NAC (on day 3) is decreased to its baseline (as low as
0.92 mg/dl). This may partially declare that high doses
NAC administration is associated with progression to-
wards acute kidney injury.
Conclusion
Considering adverse reactions observed in our study in
terms of tachycardia, high blood pressure, leukocytosis
and prolonged ventilator days and regarding the fact that
no signs of improvement were observed in terms of
mortality rate which was slightly higher for NAC group,
high dosage of NAC is not recommended in critically ill
patients with sepsis. NAC usage, even low dose, shall be
administered with great caution in critically ill patients.
Further studies on dosage and possible ceiling effect for
NAC and re-evaluating safety of that, being conducted
along with increased risk and extent of inflammatory
profile. In this study no immuno-modulating effect asso-
ciated with NAC was detected. According to SrCr varia-
tions during our study, we recommend to conduct
further studies with adequate sample size to evaluate
nephro-protective effects of NAC.
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